Total Payments
$1.8M
2024 Payments
$312,568
Companies
28
Transactions
1,514
Medicare Patients
1,149
Medicare Billing
$195,963
Payment Breakdown by Category
Other$1.3M (72.5%)
Travel$238,853 (13.4%)
Consulting$212,456 (11.9%)
Food & Beverage$38,251 (2.2%)
Education$106.89 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 352 | 71.4% |
| Travel and Lodging | $238,853 | 567 | 13.4% |
| Consulting Fee | $212,456 | 81 | 11.9% |
| Food and Beverage | $38,251 | 496 | 2.2% |
| Honoraria | $19,483 | 12 | 1.1% |
| Education | $106.89 | 6 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $674,599 | 548 | $0 (2024) |
| GlaxoSmithKline, LLC. | $286,962 | 186 | $0 (2024) |
| TESARO, Inc. | $271,017 | 291 | $0 (2019) |
| Merck Sharp & Dohme LLC | $100,672 | 90 | $0 (2024) |
| Genentech USA, Inc. | $89,892 | 55 | $0 (2019) |
| Clovis Oncology, Inc. | $89,485 | 99 | $0 (2022) |
| Genmab U.S., Inc. | $63,708 | 39 | $0 (2024) |
| ABBVIE INC. | $41,412 | 26 | $0 (2024) |
| Seagen Inc. | $37,452 | 31 | $0 (2023) |
| Myriad Genetic Laboratories, Inc. | $34,301 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $312,568 | 206 | AstraZeneca Pharmaceuticals LP ($86,576) |
| 2023 | $217,843 | 175 | GlaxoSmithKline, LLC. ($69,277) |
| 2022 | $208,543 | 161 | GlaxoSmithKline, LLC. ($98,775) |
| 2021 | $159,670 | 116 | AstraZeneca Pharmaceuticals LP ($112,738) |
| 2020 | $66,090 | 62 | AstraZeneca Pharmaceuticals LP ($34,042) |
| 2019 | $345,843 | 322 | AstraZeneca Pharmaceuticals LP ($171,621) |
| 2018 | $292,866 | 290 | TESARO, Inc. ($129,056) |
| 2017 | $174,778 | 182 | AstraZeneca Pharmaceuticals LP ($72,384) |
All Payment Transactions
1,514 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,254.00 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $102.40 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $436.89 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | In-kind items and services | $429.23 | General |
| Category: Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $105.47 | General |
| Category: Oncology | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,560.00 | General |
| 12/10/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Travel and Lodging | In-kind items and services | $282.12 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,754.00 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $122.08 | General |
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 11/30/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Travel and Lodging | In-kind items and services | $1,514.95 | General |
| Category: Oncology | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Travel and Lodging | In-kind items and services | $1,216.80 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $124.56 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,560.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Travel and Lodging | Cash or cash equivalent | $158.12 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 293 | 440 | $210,905 | $52,350 |
| 2022 | 7 | 297 | 393 | $217,439 | $51,482 |
| 2021 | 5 | 285 | 362 | $195,948 | $49,352 |
| 2020 | 6 | 274 | 375 | $170,355 | $42,778 |
Total Patients
1,149
Total Services
1,570
Medicare Billing
$195,963
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 136 | 245 | $91,570 | $22,272 | 24.3% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 18 | 18 | $48,718 | $12,442 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 46 | 77 | $22,056 | $5,253 | 23.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $17,523 | $4,513 | 25.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $13,347 | $3,383 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 21 | $11,109 | $2,887 | 26.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 14 | $3,152 | $869.54 | 27.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $3,430 | $730.23 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 113 | 181 | $66,332 | $15,676 | 23.6% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 19 | 19 | $52,275 | $13,222 | 25.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 41 | $21,628 | $5,465 | 25.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $16,519 | $4,192 | 25.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $15,552 | $3,920 | 25.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 28 | 41 | $11,712 | $2,732 | 23.3% |
| 38570 | Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | Facility | 2022 | 11 | 12 | $17,157 | $2,310 | 13.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 17 | $7,211 | $1,731 | 24.0% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2022 | 14 | 14 | $5,738 | $1,536 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $3,315 | $697.41 | 21.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 122 | 181 | $66,970 | $16,406 | 24.5% |
| 58571 | Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | Facility | 2021 | 19 | 19 | $51,383 | $13,021 | 25.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 47 | 63 | $32,634 | $8,378 | 25.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 37 | 37 | $23,421 | $5,820 | 24.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 19 | 19 | $9,937 | $2,810 | 28.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 23 | $6,003 | $1,524 | 25.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 18 | 20 | $5,600 | $1,393 | 24.9% |
About Dr. Thomas Krivak, MD
Dr. Thomas Krivak, MD is a Gynecologic Oncology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609840057.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Krivak, MD has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $312,568 received in 2024. These payments were reported across 1,514 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Krivak has provided services to 1,149 Medicare beneficiaries, totaling 1,570 services with total Medicare billing of $195,963. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location Pittsburgh, PA
- Active Since 02/14/2006
- Last Updated 08/11/2021
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1609840057
Products in Payments
- LYNPARZA (Drug) $644,108
- ZEJULA (Drug) $438,345
- JEMPERLI (Biological) $105,761
- Avastin (Biological) $89,892
- Rubraca (Drug) $89,402
- TIVDAK (Biological) $70,496
- KEYTRUDA (Biological) $68,857
- Tivdak (Drug) $58,504
- ELAHERE (Drug) $42,709
- Elahere (Biological) $31,319
- LYNPARZA (Biological) $25,553
- myChoice CDx (Device) $17,120
- MYCHOICE CDX (Device) $13,919
- HEMOBLAST (Device) $6,823
- Lenvima (Drug) $6,637
- TIVDAK (Drug) $5,204
- MYRISK (Device) $3,050
- Oncology (Device) $2,140
- XPOVIO (Drug) $838.55
- PreciseTumor (Device) $212.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Pittsburgh
Alexander Olawaiye
Gynecologic Oncology — Payments: $200,804
Gynecologic Oncology $200,804
Sarah Crafton, M.d, M.D
Gynecologic Oncology — Payments: $22,278
Gynecologic Oncology $22,278
Eirwen Miller, M.d, M.D
Gynecologic Oncology — Payments: $14,291
Gynecologic Oncology $14,291
Madeleine Courtney-Brooks
Gynecologic Oncology — Payments: $2,329
Gynecologic Oncology $2,329
Mrs. Eileen Segreti, Md, MD
Gynecologic Oncology — Payments: $1,892
Gynecologic Oncology $1,892
Jessica Berger
Gynecologic Oncology — Payments: $1,875
Gynecologic Oncology $1,875